

Atty. Docket No.: AND-1001-DV2

AMENDMENTRECEIVED
CENTRAL FAX CENTER

FEB 05 2008

In the Claims:

Please cancel claim 14, add new claims 19 and 20, and amend claims 15 and 16 as follows:

1-14. (Cancelled).

15. (Presently Amended) A column device according to claim 14 19 wherein said artificial antigen presenting cell comprises:
- a) a liposome comprising a lipid bilayer comprised of neutral phospholipids and cholesterol;
 - b) at least one GM-1 ganglioside molecule disposed in the lipid bilayer;
 - c) a cholera toxin B subunit bound to a GM-1 ganglioside molecule;
 - d) an MHC:antigen component wherein said MHC:antigen component is bound to the cholera toxin B subunit; and
 - e) an accessory molecule that can stabilize an interaction between a T cell receptor and the antigen-loaded MHC component.
16. (Presently Amended) A column device of claim 14 19 wherein said multiplicity of compartments are positioned in relation to one another in series, said compartments having a channel interconnecting adjacent compartments, said channels further having a means to isolate said compartments from one another, said compartments further having at least one entrance and at least one exit ports for receiving or expelling, respectively, a flowable medium, said ports further having a means to close said ports to impede said flowable medium.
17. (Original) A column device according to claim 16 wherein at least one of said compartments comprises solid supports capable of binding and immobilizing an

Atty. Docket No.: AND-1001-DV2

artificial APC or alternatively capable of binding directly MHC:antigen:functional molecule complexes.

18. (Original) A column device according to claim 17 wherein binding and immobilizing of an artificial APC is by a solid support capable of binding an irrelevant molecule.
19. (New) A column device comprising:
 - a) a chamber comprising a multiplicity of compartments;
 - b) in at least one of said compartments a solid support capable of binding either an MHC antigen:functional molecule complex or an artificial antigen presenting cell; and
 - c) in at least one of said compartments either an MHC antigen:functional molecule complex or an artificial antigen presenting cell.
20. (New) A column device according to claim 15 wherein said accessory molecule is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), CD49d/29(VLA-4) and antibodies or fragments thereof to ligands for each of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4).